Trial intelligence / Profile preview

Cetuximab with Carboplatin and Paclitaxel in Advanced NSCLC

NCT00097227Phase 2Completed

Sponsor
Eli Lilly and Company
Start
Nov 2004
Primary completion
Apr 2007
Modality
Monoclonal Antibodies
Countries
1
01

Overview

A Phase 2 trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Nov 2004; status: completed.

02

Drugs

KL-140
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT00097227.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00097227.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call